An interventional study of Humiome ® Post LB and Placebo in GI Issues, Bowel Movements and Gastrointestinal Symptoms, sponsored by dsm-firmenich Switzerland AG. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by dsm-firmenich Switzerland AG (part of dsm-firmenich) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this double-blind, randomized placebo-controlled study is to evaluate the effect of an 8-week supplementation of Humiome ® Post LB (170 mg) on bowel movements in healthy adult volunteers compared to Placebo adjusted on baseline. The main question[s] it aims to answer [is/are]:
Does Humiome ® Post LB improve bowel movements with self-reported GI issues?
Participants will be provided Humiome ® Post LB (170 mg) for 8 weeks and asked to complete a study diary, questionnaires, and stool samples.
dsm-firmenich Switzerland AG is the lead sponsor of 10 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Exclusion Criteria:
Meeting Irritable Bowel Syndrome (IBS) diagnostic criteria as defined by Rome IV criteria, i.e. having recurrent abdominal pain on average at least 1 day/week in the last 3 months, associated with two or more of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A postbiotic comprised of inactivated Limosilactobacillus fermentum (CNCM I-2998) and Lactobacillus delbrueckii (CNCM I-4831), together referred to as Lactobacillus LB, and fermented culture medium.
Dietary Supplement: Humiome ® Post LB
170 mg/day of micro-crystalline cellulose
Other: Placebo
Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
To evaluate the effect of Humiome ® Post LB (170 mg) supplementation on bowel movements in healthy adult volunteers compared to Placebo
To evaluate the effect of Humiome ® Post LB (170 mg) supplementation on the difference in frequency of bowel movements as assessed by the Bowel Habits Diary (BHD) in healthy adult volunteers compared to Placebo adjusted on baseline at week 8 (Day 56; between group comparison).
Time frame: Day 0 to 56
The difference in frequency of bowel movements between Humiome® Post LB and Placebo
The difference in frequency of bowel movements as assessed by the BHD at week 4 (Day 28) between Humiome® Post LB and Placebo
Time frame: Day 0 to 28
The difference in frequency of bowel movements after Humiome® Post LB and Placebo compared to baseline.
The difference in frequency of bowel movements as assessed by the BHD after Humiome® Post LB and Placebo at weeks 4 (Day 28) compared to baseline.
Time frame: Day 0 to 28
The difference in frequency of bowel movements after Humiome® Post LB and Placebo compared to baseline.
The difference in frequency of bowel movements as assessed by the BHD after Humiome® Post LB and Placebo at week 8 (Day 56) compared to baseline.
Time frame: Day 0 to 56
The difference between Humiome® Post LB and Placebo in stool consistency.
The difference at weeks 4 (Day 28) between Humiome® Post LB and Placebo in stool consistency as assessed by the Bristol Stool Scale.
Time frame: Day 0 to 28
The difference between Humiome® Post LB and Placebo in stool consistency.
The difference at weeks 8 (Day 56) between Humiome® Post LB and Placebo in stool consistency as assessed by the Bristol Stool Scale
Time frame: Day 0 to 56
The difference between Humiome® Post LB and Placebo in quality of life
The difference at weeks 4 (Day 28) between Humiome® Post LB and Placebo in quality of life as assessed by the RAND Short Form Health Survey 36 (SF-36).
Time frame: Day 0 to 28
The difference between Humiome® Post LB and Placebo in quality of life
The difference at weeks 8 (Day 56) between Humiome® Post LB and Placebo in quality of life as assessed by the RAND Short Form Health Survey 36 (SF-36).
Time frame: Day 0 to 56
The difference after Humiome® Post LB and Placebo compared to baseline in stool consistency
The difference after Humiome® Post LB and Placebo at weeks 4 (Day 28) compared to baseline in stool consistency as assessed by the Bristol Stool Scale
Time frame: Day 0 to 28
The difference after Humiome® Post LB and Placebo compared to baseline in stool consistency
The difference after Humiome® Post LB and Placebo at weeks 8 (Day 56) compared to baseline in stool consistency as assessed by the Bristol Stool Scale
Time frame: Day 0 to 56
The difference after Humiome® Post LB and Placebo compared to baseline in quality of life
The difference after Humiome® Post LB and Placebo at weeks 4 (Day 28) compared to baseline in quality of life as assessed by the RAND Short Form Health Survey 36 (SF-36).
Time frame: Day 0 to 28
The difference after Humiome® Post LB and Placebo compared to baseline in quality of life
The difference after Humiome® Post LB and Placebo at weeks 8 (Day 56) compared to baseline in quality of life as assessed by the RAND Short Form Health Survey 36 (SF-36).
Time frame: Day 0 to 56
The difference between Humiome® Post LB and Placebo in fecal microbial composition
The difference at week 8 (Day 56) between Humiome® Post LB and Placebo in fecal microbial composition (i.e., relative abundance of taxa) as assessed by shallow shotgun sequencing.
Time frame: Day 0 to 56
The difference between Humiome® Post LB and Placebo in fecal microbial composition
The difference at week 8 (Day 56) between Humiome® Post LB and Placebo in fecal bacterial diversity as assessed by shallow shotgun sequencing.
Time frame: Day 0 to 56
The difference after Humiome® Post LB and Placebo compared to baseline in fecal microbial composition
The difference after Humiome® Post LB and Placebo at week 8 (Day 56) compared to baseline in fecal microbial composition (i.e., relative abundance of taxa) as assessed by shallow shotgun sequencing.
Time frame: Day 0 to 56
The difference after Humiome® Post LB and Placebo compared to baseline in fecal bacterial diversity
The difference after Humiome® Post LB and Placebo at week 8 (Day 56) compared to baseline in fecal bacterial diversity as assessed by shallow shotgun sequencing.
Time frame: Day 0 to 56
The difference between Humiome® Post LB and Placebo in GI symptoms
The difference at weeks 4 (Day 28) between Humiome® Post LB and Placebo in GI symptoms as assessed by the Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: Day 0 to 28
The difference between Humiome® Post LB and Placebo in GI symptoms
The difference at weeks 8 (Day 56) between Humiome® Post LB and Placebo in GI symptoms as assessed by the Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: Day 0 to 56
The difference after Humiome® Post LB and Placebo compared to baseline in GI symptoms
The difference after Humiome® Post LB and Placebo at weeks 4 (Day 28) compared to baseline in GI symptoms as assessed by the Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: Day 0 to 28
The difference after Humiome® Post LB and Placebo compared to baseline in GI symptoms
The difference after Humiome® Post LB and Placebo at weeks 8 (Day 56) compared to baseline in GI symptoms as assessed by the Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: Day 0 to 56
The difference after Humiome® Post LB and Placebo in perceived benefits
The difference at week 8 (Day 56) between Humiome® Post LB and Placebo in perceived benefits as assessed by a 5-point Likert scale
Time frame: Day 0 to 56
To evaluate in healthy volunteers the effect of daily consumption of 170 mg Humiome® Post LB on safety variables
To evaluate in healthy volunteers the effect of daily consumption of 170 mg Humiome® Post LB on adverse events and serious adverse events.
Time frame: Day 0 to 56
Clinically relevant changes in blood pressure
Clinically relevant changes in blood pressure (BP) after supplementation from baseline (visit 2) at end of the study (visit 4).
Time frame: Day 0 to 56
Clinically relevant changes in heart rate
Clinically relevant changes in heart rate after supplementation from baseline (visit 2) at end of the study (visit 4).
Time frame: Day 0 to 56
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
dsm-firmenich Switzerland AG →